| 1. |
|
|
| 2. |
|
|
| 3. |
- Costa, F., et al.
(författare)
-
Management of neuroendocrine tumors : a meeting of experts from Latin America
- 2008
-
Ingår i: Neuroendocrinology. - : S. Karger AG. - 0028-3835 .- 1423-0194. ; 88:3, s. 235-42
-
Tidskriftsartikel (refereegranskat)abstract
- A panel of experts from Latin America convened in Brazil, in May of 2007, for consensus recommendations regarding the management of neuroendocrine tumors (NETs) of the gastrointestinal tract and pancreas. The recently introduced World Health Organization classification of NETs represents a step forward, but the former classification of carcinoids into foregut, midgut and hindgut is still likely to be useful in the near future. Macroscopic description of the tumor should be followed by light microscopic examination and immunohistochemical staining, whereas other techniques might not be widely available in Latin America. Surgery remains the mainstay of treatment for patients with potentially curable tumors, and adequate selection is paramount in order to optimize treatment results. Regarding systemic therapy, patients with well-differentiated tumors or islet-cell carcinomas may be categorized as having indolent disease, while patients with poorly differentiated, anaplastic, and small-cell carcinomas, or with atypical carcinoids, may be approached initially as having aggressive disease. Somatostatin analogues play a cytostatic role in indolent tumors, and chemotherapy may play a role against other, more aggressive NETs. Obviously, there is an urgent need for novel therapies that are effective against NETs.
|
|
| 4. |
- Csoregh, L, et al.
(författare)
-
Transcriptional analysis of estrogen effects in human embryonic neurons and glial cells
- 2009
-
Ingår i: Neuroendocrinology. - : S. Karger AG. - 1423-0194 .- 0028-3835. ; 89:2, s. 171-186
-
Tidskriftsartikel (refereegranskat)abstract
- Estrogen exerts many effects in the central nervous system which extend beyond regulating sexual behavior and gonadal function in reproduction. It has been shown that estrogen has a range of both neuroprotective and neuromodulatory effects, but little is known about the molecular mechanisms underlying estrogen actions in the human brain. We therefore analyzed the transcriptional response to estrogen by microarray technology in primary cell cultures of neurons and glial cells derived from 8- to 12-week human fetal brain tissue. Estrogen treatment of the cell cultures during a 7-day culture period revealed a number of genes with significantly altered expression. Fourteen genes were selected for further analysis by quantitative real-time PCR in order to confirm the gene expression changes observed by the microarray analysis. Six genes were identified with important roles in the nervous system that have not been described before to be estrogen-regulated. Three genes, IGFBP7, Transgelin and Cyr61, were further analyzed by immunostaining, and were found to be expressed in both primary neurons and glial cells. Our results indicate that estrogen may influence developing human neurons and glia through regulating expression of genes that are important for the development of the nervous system.
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Fjällskog, Marie-Louise H., et al.
(författare)
-
Treatment with Combined Streptozotocin and Liposomal Doxorubicin in Metastatic Endocrine Pancreatic Tumors
- 2008
-
Ingår i: Neuroendocrinology. - : S. Karger AG. - 0028-3835 .- 1423-0194. ; 88:1, s. 53-8
-
Tidskriftsartikel (refereegranskat)abstract
- Treatment with combined streptozotocin and liposomal doxorubicin is safe and efficient in patients with endocrine pancreatic tumors (EPTs). No cardiac toxicity was reported. BACKGROUND: The combination of streptozotocin and doxorubicin has been shown to be superior to streptozotocin and fluorouracil in the treatment of metastatic EPTs. However, the risk of cardiac toxicity from anthracyclins hampers the usefulness of the drug combination. Liposomal doxorubicin has a lower frequency of cardiac adverse events compared to doxorubicin. We wanted to assess the efficacy and safety of combined streptozotocin and liposomal doxorubicin in patients with metastatic EPTs. METHODS: Thirty patients with metastatic EPTs were recruited from three medical centers in Norway and Sweden during a time period of 3 years. All patients had histopathologically confirmed diagnoses and bidimensionally measurable lesions. 30 mg/m(2) of liposomal doxorubicin was administered on day 1 of each cycle. During the first course, 1 g of streptozotocin was given on 5 consecutive days. Thereafter, 2 g of streptozotocin was given on day 1 only. Treatment was repeated every 3 weeks. RESULTS: Twelve of 30 patients (40%) achieved an objective radiological response with a median duration of 9 months. Stabilization of disease was achieved in 17 of 30 patients (57%) for a median duration of 11 months. Only one patient had progressive disease as best response. The 2-year progression-free survival was 18% and the 2-year overall survival was 72%. The treatment was well tolerated. None of the patients experienced cardiac toxicity. CONCLUSION: We conclude that combined streptozotocin and liposomal doxorubicin is a safe and efficient treatment for EPTs. The efficacy seems to be comparable to that of combined streptozotocin and doxorubicin, whereas the cardiac toxicity clearly favors using the liposomal drug combination. 2008 S. Karger AG, Basel.
|
|
| 10. |
|
|
